GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
786.00
+66.00 (9.17%)
Last updated: Apr 16, 2026, 11:48 AM KST
Market Cap65.28B -60.8%
Revenue (ttm)23.04B -35.5%
Net Income-51.85B
EPS-629.00
Shares Out90.67M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,787,479
Average Volume2,205,858
Open720.00
Previous Close720.00
Day's Range719.00 - 810.00
52-Week Range618.00 - 4,270.00
Beta0.69
RSI37.20
Earnings DateMay 14, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.

Financial Statements